Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors

NCT07042100 is registered in ClinicalTrials.gov with Sun Pharma Advanced Research Company Limited as lead sponsor.

NCT NCT07042100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07042100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors
Lead sponsor
Sun Pharma Advanced Research Company Limited
Phase
Phase 1
Overall status
Recruiting
Start date
August 12, 2025
Completion date
August 31, 2030
Enrollment
177 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors